About Epitalon Source
Twenty-five years of peer-reviewed research on the AEDG tetrapeptide — indexed, cited, and published here as an independent editorial digest. Not a clinic, not a vendor, not a protocol service.
What This Site Is
Epitalon Source is an independent editorial project that publishes summaries of the peer-reviewed research literature on epitalon (the AEDG tetrapeptide, Ala-Glu-Asp-Gly). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The "source" in the domain name refers to the research record: this site's purpose is to be a primary-sources-first reading surface for the epitalon literature — the numbers, the citations, the species, the doses, the methodological caveats — organized as an analytics readout of what has actually been measured. The name is not a claim to be a vendor, supplier, or distribution channel.
Epitalon vs. Epithalamin: Synthetic Peptide vs. Gland Extract
What is the difference between epithalon and epithalamin?
Epithalamin is a crude polypeptide fraction extracted from bovine pineal glands, used in Russian clinical practice since the 1970s. It contains a mixture of low-molecular-weight peptides, including the AEDG tetrapeptide. Epithalamin received limited clinical approval in Russia for specific age-related indications under Russian regulatory standards.
Epitalon is the synthetic four-amino-acid peptide — Ala-Glu-Asp-Gly — identified by Khavinson and colleagues as the putative active component of epithalamin. The synthetic form allows precise dosing, eliminates batch variability inherent in animal-derived extracts, and removes zoonotic contamination concerns.
The research record for synthetic epitalon largely replaces earlier epithalamin studies after the mid-1990s, when the synthetic route became the standard for new experiments. The human mortality study from Khavinson and Morozov (2003, PMID 14523363) used both epithalamin and epitalon in different arms — making it a direct comparison of the extract and its synthetic derivative in the same cohort.[9]
The regulatory status differs: epithalamin (the extract) has Russian clinical approval for specific indications; synthetic epitalon has no equivalent regulatory standing in Western markets.
Epitalon vs. Oral Telomerase Supplements
How is epitalon different from a standard telomerase supplement?
Most oral "telomerase supplements" — cycloastragenol and related compounds are the most-studied examples — operate through indirect pathway stimulation, typically via astragalus-derived formulations that have been evaluated in human studies for telomere-length effects.
Epitalon is a peptide administered parenterally (subcutaneous injection in most published research) that appears to directly regulate hTERT gene expression — the rate-limiting step for telomerase activity — in a mechanistically distinct approach.[1][2][22] The 2025 independent replication specifically documented hTERT mRNA upregulation as the primary molecular event.[22]
Comparative efficacy data between epitalon and oral telomerase activators have not been published. The route of administration differs fundamentally — oral peptide bioavailability is generally very low for unmodified short peptides, which is why the published epitalon protocols use parenteral administration.
The Single-Source Caveat
The most important qualifier on the epitalon literature is its provenance: the overwhelming majority of published research originated from a single research group — Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology in Russia, active from the 1970s through the present.
This is not a disqualifier for the findings — single-group research programs produce valid science — but it is a limitation on the certainty that can be placed on results. Independent Western replication was almost entirely absent until 2025, when Al-Dulaimi and colleagues at Northumbria University published the first independent cell-culture confirmation of epitalon's telomere-lengthening effect.[22]
That paper also introduced the ALT activation finding in cancer cell lines — a result the Khavinson group had not previously documented and that carries safety implications requiring further investigation. The emergence of a second research group studying epitalon with independent methodology represents a maturation of the evidence base that the site tracks as a priority signal.
21 of 25 citations on this site originate from the Khavinson group. The four 2025 independent studies (refs 21–24) include the first non-Khavinson telomere replication. This provenance note appears on every content page that draws on this literature.